0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover462.15%IV-142.72%PremiumAug 16, 2024Expiry Date4.41Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.5506Delta0.1065Gamma0.61Leverage Ratio-0.0291Theta-0.0036Rho-0.33Eff Leverage0.0032Vega
Sagimet Biosciences Stock Discussion
Larger Image: tradingview.com...
$Sagimet Biosciences(SGMT.US)$
NEWS
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
In the fast-paced world of biotech investments, staying ahead of the curve is crucial for investors seeking substantial returns. Sagimet Biosciences (NASDAQ: SGMT), a company that has recently garnered significant attention from Leerink Partners, an esteemed investment firm, is one such entity that demands your immediate ...
$Leap Therapeutics(LPTX.US)$ Phase 2
$Vera Therapeutics(VERA.US)$ Phase 2b
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$Akero Therapeutics(AKRO.US)$ Phase 2b
$Spruce Biosciences(SPRB.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Annexon(ANNX.US)$ Phase 2a
$Roivant Sciences(ROIV.US)$...
SAN MATEO, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ("Sagimet") (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the commencement of an underwritten public offering of 9,000,000 shares of its Series A common st...
No comment yet